People · Operator
Named in public records as an officer, director or promoter · active 2010–2025 · Other, Other Technology, Software / Tech, Other Energy, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| 180 Life Sciences Corp. | — | Other | Growth/Late | $454.6M | $4.2B | 2024 |
| LeafLink, Inc. | — | Other Technology | Series C | $81.1M | $940.2M | 2015 |
| Bevy Labs, Inc. | — | Software / Tech | Series B | $55.0M | $956.5M | 2020 |
| Pogo Financial Inc. | — | Other Technology | Series A | $9.0M | $249.7M | 2019 |
| Mhpi Iii, Llc | — | Other | Series A | $5.0M | $12.5M | — |
| EPC Power Corp. | — | Other Energy | Seed | $4.3M | $38.9M | 2015 |
| Sortis Holdings, Inc. | — | Other | Seed | $2.3M | $12.7M | 2022 |
| Micromidas, Inc. | — | Other Technology | Seed | $2.2M | $73.5M | 2010 |
| Divyze, Inc. | — | Other Health Care | Pre-Seed | $250K | $2.6M | 2022 |
| Click Materials Corp. | — | Other | Pre-Seed | $240K | $5.5M | 2019 |
| Mhpi Ii Llc | — | Other | Pre-Seed | $225K | $5.2M | 2010 |
Ryan Smith at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ryan Smith on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Reynolds | 2 | 4 |
| Jamie Smith | 2 | 3 |
| Adam Ludwin | 1 | 10 |
| Ryan Sweeney | 1 | 5 |
| Lawrence Steinman | 1 | 4 |
| Kobie Fuller | 1 | 4 |
| Blair Jordan | 1 | 3 |
| Ian Loizeaux | 1 | 3 |
| James N. Woody | 1 | 3 |
| Jared Weinstein | 1 | 3 |
| Alex Millar | 1 | 3 |
| CASEY MCGRATH | 1 | 3 |
| Andrew Greenfield | 1 | 2 |
| Stephen Shoemaker | 1 | 2 |
| Jay Goodman | 1 | 2 |
| Devon Gundry | 1 | 2 |
| HOWARD MICHALSKI | 1 | 2 |
| Zachary Silverman | 1 | 2 |
| Eric Van Lent | 1 | 1 |
| Stephen H. Shoemaker | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.